A brief report of toxicity end points of HER2 vaccines for the treatment of patients with HER2+ breast cancer
Ricardo Costa,1 Saif Zaman,2 Susan Sharpe,3 Irene Helenowski,4 Colleen Shaw,1 Hyo Han,1 Hatem Soliman,1 Brian Czerniecki1 1Department of Breast Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA; 2Morsani College of Medicine, University of South Florida, Tampa, FL, USA; 3...
Main Authors: | Costa R, Zaman S, Sharpe S, Helenowski I, Shaw C, Han H, Soliman H, Czerniecki B |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2019-01-01
|
Series: | Drug Design, Development and Therapy |
Subjects: | |
Online Access: | https://www.dovepress.com/a-brief-report-of-toxicity-end-points-of-her2-vaccines-for-the-treatme-peer-reviewed-article-DDDT |
Similar Items
-
HER-2/neu-targeted immunoprevention of breast cancer
by: Sas, Sheena Emm
Published: (2007) -
Murine Dendritic Cells Grown in Serum-Free Culture Show Potent Therapeutic Activity when Loaded with Novel Th Epitopes in an Orthotopic Model of HER2<sup>pos</sup> Breast Cancer
by: Loral E. Showalter, et al.
Published: (2021-09-01) -
Cancer Vaccines, Treatment of the Future: With Emphasis on HER2-Positive Breast Cancer
by: Sandeep Pallerla, et al.
Published: (2021-01-01) -
Prognostic value of HER3, PTEN and p-HER2 expression in patients with HER2positive breast cancer
by: Sylwia Dębska-Szmich, et al.
Published: (2015-05-01) -
Enhanced Immunogenicity of Engineered HER2 Antigens Potentiates Antitumor Immune Responses
by: Insu Jeon, et al.
Published: (2020-07-01)